Company Name : Akston Biosciences Corporation

Wednesday, March 8, 2023 5:42PM IST (12:12PM GMT)
Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA
BEVERLY, Mass., United States & Bangalore, Karnataka, India
  • Akston has reclaimed all commercial rights to AKS-452, its room temperature stable COVID-19 vaccine
  • Akston is continuing its progress to secure Emergency Use Authorization (EUA) in India and has begun working with a new CDMO to produce AKS-452

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it has ended its AKS-452 licensing, manufacturing, and commercialization agreement with Stelis Biopharma Limited, an arm of Strides Pharma Science Ltd.


Akston has reclaimed all rights to AKS-452, a room temperature stable, low-cost, protein subunit COVID-19 vaccine. AKS-452 has completed a Phase II/III clinical trial in India, with data showing robust safety profile and a 91% seroconversion rate at Day 56. Volunteers in the study had antibody titers that persisted at statistically-significant high levels through six months, with serum showing protection against variants of concern, including Delta and Omicron.


Akston is now working with a new CDMO in India to produce the promising AKS-452 COVID "universal" booster vaccine.


The results of a Phase I/II randomized, open-labelled study in The Netherlands and published in Vaccine showed that seroconversion rates reached 100% with enhanced potencies of SP/RBD-ACE2 binding inhibition and live virus neutralization.


In a Phase II study in the Netherlands of AKS-452 as a “universal” booster vaccine, 93% of subjects previously vaccinated with Pfizer, Moderna, Johnson & Johnson (Janssen), and AstraZeneca vaccines showed an increase in neutralizing antibody titers after receiving a single dose. The average neutralization titers across all subjects increased 4-fold against the Wuhan strain and 5-fold against the Omicron variants at Day 28. There were no safety issues reported.


Todd Zion, Ph.D., President & CEO of Akston Biosciences, said,“I am confident that AKS-452 can attain Emergency Use Authorization (EUA) in India, especially as a ‘universal’ booster vaccine capable of increasing and broadening people’s immune response as their previous immunity wanes and new variants arise. We concluded that Akston and a different CDMO were better placed to move ahead the AKS-452 development plan at a rapid pace, so we reclaimed the rights.”


About Akston Biosciences


Akston Biosciences Corporation leverages its Ambifect™ Fc-fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co.), Akston owns and operates a cGMP biologics cleanroom facility that manufactures kilogram-scale batches of drug substance. This, along with its research and process development laboratories, are located at its Beverly, Mass. location. Additional information is available at




Click here for Media Contact Details

Linda Pendergast-Savage
Birnbach Communications for Akston Biosciences
1-508-224-7905 |

Similar News

Quantela, a Technology Partner That Digitizes Urban Infrastructure, Partners with Digital Alpha and Starlite Media for USD 50 Million to Revolutionize Retail Media Networks

24/03/2023 6:48PM

Quantela, an urban infrastructure solution provider, and Starlite Media, a leading retail media network, announced today a strategic partnership to drive, expand and optimize Starlite's digital retail media network. ...

SMT Chosen as Exclusive Distributor of Penumbra’s Latest Mechanical and Computer-Aided Aspiration Technology in India to Address Blood Clots in the Heart and Body

24/03/2023 2:15PM

SMT announced today that it has been selected as the exclusive distributor of Penumbra’s peripheral and coronary vascular thrombectomy technologies in select domestic geographies in India.